Filing summary
Entity and period: The supplied document is Helius Medical Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 14, 2019—not a filing for Solana Co. The filing reports annual results; it provides limited standalone fourth-quarter detail.
Business context
Helius is a development-stage neurotechnology company focused on its Portable Neuromodulation Stimulator (PoNS), a tongue-based, non-invasive neurostimulation device used with targeted therapy. PoNS was authorized in Canada in October 2018 for chronic balance deficit associated with mild-to-moderate traumatic brain injury (mmTBI). U.S. FDA and EU marketing reviews were pending at year-end.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0.478 million | None |
| Operating expenses | $27.153 million | $22.853 million |
| Operating loss | $26.675 million | $22.853 million |
| Net loss | $28.623 million | $28.024 million |
| Cash used in operations | $19.621 million | $19.325 million |
| Cash at year-end | $25.583 million | $5.562 million |
| Working capital | $22.757 million | $1.897 million |
- The $0.478 million revenue was a license fee under the Canadian strategic alliance, not product sales. The filing says no commercial product or service revenue had been generated.
- R&D expense fell by $4.448 million, mainly as the registrational trial and device design work concluded. General and administrative expense rose by $8.748 million, including higher stock compensation and commercialization spending.
- Operating cash outflow was nearly unchanged year over year. Financing provided $40.028 million, chiefly from stock offerings and warrant/option exercises; 2018 offerings issued shares and warrants and diluted existing holders.
- Total assets were $27.827 million and total liabilities $17.973 million at year-end. Liabilities included $13.769 million of derivative financial instruments, primarily warrants. No conventional borrowing balance is identified in the supplied balance sheet.
- The filing reports an accumulated deficit of $94.992 million. It provides no meaningful product gross margin data, as commercial product sales had not begun.
Material changes, outlook and risks
- Helius raised $38.5 million in gross proceeds from two 2018 public offerings. Cash increased by $20.021 million during the year, but cash used in operations remained substantial.
- The auditor and management identified substantial doubt about the company’s ability to continue as a going concern. Management said existing resources were expected to fund operations only through the third quarter of 2019 without additional capital. Additional financing was not assured; the filing warns of potential operating reductions or wind-down if funding could not be obtained.
- The FDA placed its review of the PoNS de novo classification and 510(k) request on administrative hold pending additional information. Helius submitted its response in March 2019 and expected FDA review to resume; authorization was not assured. The CE Mark application was also pending.
- Clinical results were mixed in an important respect: the registrational trial’s primary effectiveness endpoint was not reached because the low-frequency comparison arm also showed a substantial response. The pooled secondary analysis reported mean SOT balance-score improvements of 18.3 points at two weeks and 24.6 points at five weeks. The company reported no serious device-related adverse events.
- A separate 26-week study reported that average balance-score gains after 14 weeks of treatment were maintained through a 12-week washout. These findings do not establish regulatory approval or commercial effectiveness beyond the studied populations and protocols.
- In Canada, two clinics began treating patients in March 2019 after initial commercial orders. Helius expected early access to rely substantially on self-pay, with broad government and commercial payer coverage potentially taking at least 24 months. The company also planned further studies in multiple sclerosis and stroke, subject to regulatory requirements and funding.
- Key risks include regulatory delay or rejection, uncertain reimbursement and adoption, dependence on additional financing, single-product and third-party manufacturing/distribution exposure, competition, and potential dilution. Helius also reported a 2017 business-email-compromise loss of approximately $0.2 million.
Important facts for investors to verify
- Confirm the filing identity: the source is Helius Medical Technologies, Inc., despite the request metadata naming Solana Co.
- Check subsequent financing, cash burn and actual runway against the stated expectation that cash would last through Q3 2019.
- Verify subsequent FDA and EU regulatory decisions, including any conditions or additional clinical requirements.
- Assess Canadian sales, clinic activity, product economics and payer reimbursement; the reported 2018 revenue was a license fee, not device sales.
- Review warrant terms, derivative-liability valuation and potential dilution from outstanding options and warrants.
- Evaluate the clinical evidence with attention to the unmet primary endpoint, pooled secondary analysis, sample sizes and durability-study limitations.